A 48-year-old woman with chronic hypertension (BP 165/95 mmHg) is found to have Grade II hypertensive retinopathy on routine fundoscopy. She is asymptomatic. Which agent is the preferred first-line oral antihypertensive for long-term management of her hypertension to prevent progression of retinopathy?

Explanation

## Chronic Hypertensive Retinopathy: Long-Term Management ### Clinical Context This patient has **Grade II (moderate) hypertensive retinopathy** without acute end-organ damage (no papilledema, no retinal hemorrhages). The goal is sustained BP control to prevent progression to malignant hypertension and further retinal damage. ### Drug of Choice: Losartan (ARB) **Key Point:** Angiotensin II receptor blockers (ARBs) like losartan are preferred first-line agents for chronic hypertension with retinopathy because they: - Provide renal and retinal protection via angiotensin II blockade - Reduce intraglomerular pressure and prevent glomerulosclerosis - Have proven cardiovascular and renal benefits in hypertensive patients - Are well-tolerated with minimal side effects - Prevent progression of hypertensive retinopathy ### Comparison of Options | Agent | Class | Retinal/Renal Protection | Onset | Suitability for Chronic HTN | | --- | --- | --- | --- | --- | | **Losartan** | ARB | Excellent (blocks Ang II) | 1–2 weeks | **First-line** | | **Nifedipine IR** | Calcium channel blocker | Moderate | Minutes (too rapid) | Not ideal; IR form causes reflex tachycardia | | **Propranolol** | Non-selective β-blocker | Poor | 1–2 hours | Outdated; less effective for retinal protection | | **Furosemide** | Loop diuretic | None; may worsen | Hours | Inappropriate; not antihypertensive | **High-Yield:** ACE inhibitors and ARBs are the preferred agents for hypertension with end-organ damage (retinopathy, nephropathy, LVH) because they reduce proteinuria and slow progression of microvascular disease. Losartan is equivalent to lisinopril but better tolerated (no cough). ### Mechanism of Retinal Protection ```mermaid flowchart TD A[Chronic Hypertension]:::outcome --> B[Endothelial dysfunction<br/>Increased Ang II]:::outcome B --> C{Losartan blocks<br/>AT1 receptor}:::decision C -->|Yes| D[Reduced intraglomerular<br/>and retinal capillary pressure]:::action C -->|No| E[Progression of retinopathy<br/>Microaneurysms, hemorrhages]:::urgent D --> F[Prevention of retinal damage<br/>Reduced proteinuria]:::outcome ``` **Clinical Pearl:** In hypertensive retinopathy, the goal is to reduce BP gradually (not acutely) to avoid sudden changes in retinal perfusion. ARBs and ACE inhibitors achieve this while providing organ protection. [cite:Harrison 21e Ch 297; Kanski & Bowling Ophthalmology Ch 11]